Thryv Therapeutics Inc. announces $30 million Series B financing led by InClin, Inc. to support the ASPIRE-HF study for heart failure.
Amount Raised
$30 Million
Round Type
Series B
San FranciscoBiotechnologyHealth CareTherapeuticsInvestors
Description
Thryv Therapeutics Inc. completed a $30 million Series B financing led by InClin, Inc. and supported by existing investors. The funds will be used for the ASPIRE-HF study in patients with heart failure
Quick answer
Thryv Therapeutics raised $30 Million in a Series B round, dated November 3, 2026. Investors: Amplitude Ventures, Investissement Québec, Lumira Ventures, adMare BioInnovations, CTI Life Sciences Fund, Alexandria Venture Investments, InClin, Inc. and Fonds De Solidarité Ftq. Thryv Therapeutics is based in San Francisco, California, United States.
- How much did Thryv Therapeutics raise?
- Thryv Therapeutics raised $30 Million in a Series B round on November 3, 2026.
- Who invested in Thryv Therapeutics?
- Amplitude Ventures, Investissement Québec, Lumira Ventures, adMare BioInnovations, CTI Life Sciences Fund, Alexandria Venture Investments, InClin, Inc. and Fonds De Solidarité Ftq are named as investors in this round.
- What does Thryv Therapeutics do?
- Thryv Therapeutics Inc. is a clinical-stage biotechnology company focused on developing precision therapies for inherited channelopathies and cardiometabolic diseases.
- Where is Thryv Therapeutics based and how big is it?
- Thryv Therapeutics is based in San Francisco, California, United States.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Thryv Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Lifeplex Science raised $5.3M (Series A) on November 13, 2026.
- Orakl Oncology raised $34M (Series A) on November 12, 2026.
- Neurosterix raised $105M (Series B) on November 11, 2026.
- VectorY raised $83M on November 11, 2026.
- Oyster Therapeutics raised $60M (Series A) on November 10, 2026.
- SRTD biotech raised $35M (Seed) on November 9, 2026.
Who to call at Thryv Therapeutics, and when
A new round usually means Thryv Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Thryv Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Thryv Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Thryv Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Thryv Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansThryv Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.